The skin disease Buruli ulcer, caused by Mycobacterium ulcerans, is the third most common mycobacterial disease after tuberculosis and leprosy and mainly aff ects remote rural African communities. Although the disease is known to be linked to contaminated water, the mode of transmission is not yet understood, which makes it diffi cult to propose control interventions. The disease is usually detected in its later stages, when it has caused substantial damage and disability. Surgery remains the treatment of choice. Although easy and eff ective in the early stages of the disease, treatment requires extended excisions and long hospitalisation for the advanced forms of the disease. Currently, no antibiotic treatment has proven eff ective for all forms of M ulcerans infection and research into a new vaccine is urgently needed. While the scientifi c community works on developing non-invasive and rapid diagnostic tools, the governments of endemic countries should implement active case fi nding and health education strategies in their aff ected communities to detect the disease in its early stages. We review the diagnosis, treatment, and control of Buruli ulcer and list priorities for research and development.
Introduction
Buruli ulcer is primarily an infection of the subcutaneous fat caused by the environmental pathogen Mycobacterium ulcerans. Although the disease has a low mortality rate, it has a huge socioeconomic impact on aff ected populations and is a public-health issue in terms of morbidity, treatment, and functional disabilities.
The clinical lesion of Buruli ulcer usually starts as a painless subcutaneous nodule that secondarily ulcerates, presenting characteristic undermined edges (fi gure 1). Other pre-ulcerative forms are papules aff ecting only the skin (observed more often in Australia than other parts of the world), plaques (large fi rm, painless, and raised lesions), and oedema (severe form of the disease). M ulcerans produces a toxin, mycolactone, which induces necrosis and ulceration by its cytotoxic and immunosuppressive properties. Some patients develop bone (osteomyelitis) and joint lesions through contiguous or haematogenous spread of M ulcerans. Later in the natural history of the disease spontaneous healing can occur, although the mechanisms of this spontaneous healing are unclear.
1 Healing takes months and can cause deep scarring, retractions, and deformity. Death is a rare complication. Various recurrence rates after surgical treatment have been reported, from 6·1% within 7 years of follow-up 2 to 16% after a follow-up period of 1 year. 3 Since 1980, there has been a large increase in the detection rate of the disease. Buruli ulcer is now the third most common mycobacterial infection in human beings after tuberculosis and leprosy, and is the most poorly understood of the three diseases. The disease often occurs in localised and remote areas where populations have limited access to medical care. The median age of Buruli ulcer patients is about 15 years; the distribution of age-specifi c detection rates peaks at 10-14 years and 75-79 years. 4 Buruli ulcer has been reported or suspected in 30 tropical countries worldwide, including Australia, but west Africa is the most aff ected region (fi gure 2). 6 Cases have also been reported in nontropical areas. 6 The number of cases reported in some countries of west Africa is substantial: 5700 between 1989 and 2003 in Benin, with a Buruli ulcer detection rate of 21·5 per 100 000 in 1999 in the Zou region; 7 17 000 between 1978 and 2003 in Côte d'Ivoire, where prevalence reaches 16% in some villages; 8 in Ghana, a national survey done in 1999 detected 5619 cases (overall crude national prevalence of 20·7 per 100 000 but 158·8 per 100 000 in the most aff ected districts), of which Review almost 50% were at the ulcerative stage. 9 However, most of these data come from passive case detection and are probably under-estimates of the extent of the problem worldwide. 10 Part of the explanation for the emerging character of the disease could be an increase in public and scientifi c awareness. Buruli ulcer has long gone largely unnoticed, possibly because it occurs in remote rural communities that are poorly covered by national health surveillance systems. Additionally, many of the aff ected populations do not seek health services because of fi nancial constraints, beliefs that the treatment does not work, fear of surgery and anaesthesia, or superstition and stigma. 11, 12 However, some researchers 7, 13 have concluded that the emergence of the disease is not only detection bias but also an increase in the exposure of aff ected populations. Outbreaks appear to be related to environmental changes (deforestation, agriculture, and hydraulic installations) involving surface water. 14 Areas aff ected by Buruli ulcer disease are located near stagnant or slow-fl owing water areas. Despite epidemiological 15 and PCR data [16] [17] [18] suggesting a link between M ulcerans and water, the transmission mechanism of the disease is not known. One of the obstacles to researching this transmission mechanism is the extreme diffi culty in isolating M ulcerans from environmental samples. The detection of the mycobacterium is usually done through PCR using the IS2404 target but, although very useful, this target might not be specifi c for M ulcerans, since it has also been found in other mycobacteria. [19] [20] [21] Only two pure cultures of M ulcerans have ever been obtained from environmental sources. 1 Transmission to human beings is probably direct, through skin trauma from the watersoil reservoir, but the role of insects is increasingly suspected. 16 It has been demonstrated that the bite of infected naucoridae (aquatic predator insects) can transmit the disease to laboratory mice. 22 Because M ulcerans has been detected by PCR in diff erent organisms from the aquatic ecosystem, diff erent experimental models of transmission with passive intermediary hosts involving algae, naucoridae, aquatic snails, and fi sh have recently been suggested. 17, 22, 23 M ulcerans has also been detected by PCR in mosquitoes in Australia, but their role in transmission has still to be demonstrated. 18 Migratory birds might be involved in the dissemination of the disease between wetlands, leading to the appearance of new foci. 17 Diff erent factors might infl uence the clinical presentation of the disease-eg, the site of infection, the size of inoculum, the nature of the transmitting agent, the history of a trauma, and also the immune response of the host. An immune response mediated by Th1 lymphocytes is protective against Buruli ulcer disease but Th2 responses are not. It has been suggested that coinfection with schistosomiasis could predispose individuals infected with M ulcerans to express the disease by a shift to the Th2 immune response but no association has been found between the two diseases. 24, 25 Strong IgM antibody responses to M ulcerans seem more frequent in patients with active Buruli ulcer than in healthy members of their families. 26 HIV infection 
Review
has not been reported as a risk factor for Buruli ulcer 27 but severe clinical forms of the disease have been described in HIV-positive patients. 28 In three HIVpositive Buruli ulcer patients in Akoloninga, Cameroon, we observed that the healing process improved when the patients started antiretroviral treatment (EC, unpublished data).
Case detection and diagnosis
The burden of Buruli ulcer disease (ie, costs, extensive surgery, long hospitalisation, and development of debilitating sequelae) is mainly due to the late detection of cases. Patients often seek medical treatment when experiencing the severe and advanced stages of the disease. Late presentation is caused by several factors: (1) the disease itself-nodules can go unnoticed and when the ulcer appears, it progresses slowly, is painless, and the patient does not have systemic symptoms; (2) beliefs and stigma regarding the origin of the disease (namely witchcraft) making aff ected individuals reluctant to seek help; and (3) limited geographic, fi nancial, and cultural access to medical care.
Although the clinical diagnosis of the ulcerative form is straightforward, it is more diffi cult for the nodule, plaque, and oedematous forms. The diff erential diagnosis includes pyogenic abscess in nodules, erysipelas in plaques, and cellulites in acute oedematous forms of the disease. 29 In endemic areas, every suspicious lesion should be treated as an M ulcerans infection until proven otherwise.
Tests for Buruli ulcer diagnosis include the following methods: (1) direct smear examination with ZiehlNeelsen staining to detect the presence of acid-fast bacilli in a smear done from a swab or a biopsy; (2) culture on Löwenstein-Jensen medium at 32ºC (however, this method is diffi cult, expensive, has a low sensitivity, and results are available only after 6-12 weeks); (3) histopathology; and (4) PCR, which allows quick detection, and is suffi ciently specifi c in patient samples because other environmental mycobacterium will not be present in patient samples as they are in environmental samples, the IS2404 target is suffi ciently specifi c.
The sensitivity of these diagnostic tests 30 is estimated to be 40-80% for Ziehl-Neelsen staining, 20-60% for culture, over 90% for histopathology, and over 90% for PCR. In practice, however, the diagnosis of Buruli ulcer is based on clinical aspects and rarely confi rmed because of limited access to laboratory services. Ziehl-Neelsen staining is the only method that could be easily implemented in the fi eld. PCR is the quickest and most sensitive diagnostic tool but, unfortunately, presents technical diffi culties (eg, cold chain requirement, stable electric supply and qualifi ed laboratory staff ) for fi eld implementation. This technical issue could be overcome by the recent development of a dry reagent-based PCR. 31 According to WHO, confi rmed cases require two positive results among the diagnostic tests, 30 but WHO considers the possibility that one positive result might be suffi cient in a context of a high clinical suspicion.
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Treatment
Surgery remains the main treatment for Buruli ulcer. Wide excision margins, including healthy tissues, are recommended to stop the infection and prevent recurrence or relapse at the same site. Surgery in the early stages of infection is curative and highly costeff ective, since it requires a simple excision followed by an immediate closure. However, in the disease's later stages, wide and traumatising excisions are needed, followed by skin grafting, and long hospital stays. Physiotherapy after surgery might help to prevent functional disabilities. To avoid or limit the surgical excision, diff erent medical approaches have been explored-eg, topical treatments, hyperbaric oxygen therapy, and antibiotic treatments (panel).
Topical treatments
Some authors have suggested that nitrogen oxides, at a concentration of 6%, could kill M ulcerans in Buruli ulcer lesions quickly, as it has been shown in vitro. 33 A small double-blind randomised controlled trial testing the daily application of a cream releasing nitrogen oxides on ulcers of less than 15 cm in diameter for at least 6 weeks has been done in Ghana. 34 It showed a signifi cant reduction of the size of the ulcer over time in the intervention group (p=0·03). However, those results should be interpreted with caution since the two groups were not comparable and only four patients had laboratory confi rmed disease. Further trials are needed to defi ne the optimum frequency and duration of application.
In a case series 35 phenytoin powder appeared promising in accelerating the healing process of ulcerative Buruli ulcer lesions and decreasing the risk of hypertrophic scarring. In a small randomised controlled 36 ulcer surface reduction of more than 50% was observed more frequently in patients treated with phenytoin powder (72%) compared with placebo (35%), especially in young people (<30 years) and ulcers of less than 30 cm in diameter. It has also been suggested that clay allows a quick resolution of oedema, a vigorous but non-aggressive debriding of ulcers, and accelerates healing without surgery other than skin grafting. 37 Local heat at 40°C, applied to eight patients with ulcers of less than 10 cm diameter in Zaire, 38 led to complete healing without surgery (except for the initial removal of necrotic tissues) and no relapse at 22 months of follow-up. However, the practicality of this treatment in remote areas (high costs, minimum infrastructure such as electricity, and total confi nement to bed for at least 2 weeks) is limited.
Systemic treatment
Although oxygen therapy seems to be ineff ective, 39 it is believed that antibiotic treatments, eventually combined with heparin, can improve the outcome of Buruli ulcer disease. 
The use of monotherapies is generally ineff ective. Clofazimine, an anti-leprosy drug evaluated in a large randomised controlled trial, 43 did not improve the healing process, nor reduce the number of surgical excisions, nor prevent recurrences. A randomised controlled trial of co-trimoxazole (trimethoprimsulfamethoxazole) 45 did not show any benefi ts and was not conclusive because of the small sample size and because the treatment groups diff ered with regard to initial surgical treatment and duration of follow-up. In a cases series in Côte d'Ivoire in which diff erent antibiotics were used in monotherapy for 1 month, the lowest failure rate was associated with streptomycin. 46 Studies in animal models showed that aminoglycosides (eg, streptomycin and amikacin) and rifampicin have a strong bactericidal activity when used alone. 47, 48 However, M ulcerans could become resistant to rifampicin if this drug is used in monotherapy. 49 Based on these results and some observational studies, WHO recommended a combination of rifampicin and streptomycin for 8 weeks for the management of Buruli ulcer. 50 With this treatment, experts hope to reduce the indications of surgery or, at least, the extent of the surgery and hope also to decrease the relapse rate. A small clinical trial showed that a minimum of 4 weeks of this combination inhibits the growth of M ulcerans in nodules and plaques, confi rmed by PCR and/or acidfast bacilli examination and/or culture. 40 However, the size of this trial is too small to conclude eff ectiveness of this treatment and its effi cacy in preventing relapse or dissemination has not yet been evaluated.
It has been suggested that heparin combined with rifampicin and aminoglycoside treatment could improve blood circulation and antibiotic penetration. A case study report showed excellent results of this combination in a young girl who could not be operated on because of the location of the lesion on the face. 41 This observation has been followed by a non-blinded randomised controlled trial comparing local nursing alone with local nursing plus the tri-therapy of heparin, rifampicin, and amikacin. 42 In the group receiving only dressing care, 100% of the patients needed surgery, whereas in the group receiving the tri-therapy, only 20% had to go through surgery. However, the design of the study makes it diffi cult to assess the role of heparin versus that of the antibiotics.
The combination of clarithromycin and rifampicin is regularly used as part of standard treatment protocols in Australia 51 but its effi cacy has never been evaluated. In a randomised controlled trial done in Côte d'Ivoire, 44 the combination of rifampicin and dapsone showed ulcer size reduction in the treatment group compared with the placebo group but these results are inconclusive due to the small sample size and the imbalances of the ulcer size at baseline.
Some antimicrobial agents have shown promising results in vitro and in animal models (table 2) but clinical trials are needed to assess their eff ectiveness in human beings. In vitro, M ulcerans is highly susceptible to fl uoroquinolones 52 but in mice, their eff ect is bacteriostatic. 49 Sitafl oxacin, a new fl uoroquinolone, has been demonstrated to be superior to other fl uoroquinolones both in vitro and in vivo, especially when combined with rifampicin. 53, 54 The combination of rifampicin, clarithromycin, and sparfl oxacin has been tested in mice but it is not as eff ective as rifampicin with an aminoglycoside. 49, 55, 56 Rifalazil (benzoxazinorifamycin or KRM-1648), derived from rifampicin, seems to have a better inhibitory activity than rifampicin in mice. 57 In-vitro studies showed that epiroprim, a dihydrofolate reductase inhibitor, has a good inhibitory activity on the growth of M ulcerans and that there is a strong synergic activity against M ulcerans 58 when dapsone and epiroprim are combined. At least one new drug (a diarylquinoline known as R207910) has a remarkable activity in vitro against many mycobacterial species, including M tuberculosis and M ulcerans. 59 Overall, no antibiotic combination has proven eff ective in the management of Buruli ulcer up to now. Despite a lack of evidence, it is believed that antimycobacterials in the right combination for the appropriate duration may reduce the healing time for ulcers and the recurrence rate, and might help avoid surgery or at least limit its extent. Rifampicin seems to 47 However, the long-term side-eff ects of aminoglycosides are quite substantial, and their eff ectiveness has not yet been formally demonstrated by well conducted clinical trials. Moreover, they are contraindicated in pregnant women and the injectable pathway is not ideal in the context of the HIV epidemic in sub-Saharan Africa. Fluoroquinolones do not have the drawbacks of the aminoglycosides and have good bone penetration. However, these drugs are contraindicated in sun exposure, in growing children, and in pregnant and breast-feeding women. Another important concern is that rifampicin and streptomycin are eff ective antituberculosis drugs. Their use in Buruli ulcer, without excluding concomitant active tuberculosis, might increase the risk of developing resistant tuberculosis, which could become a real threat if Buruli ulcer disease continues to progress as it has over the past 20 years. In addition, the progression of the HIV epidemic makes it more likely that more Buruli ulcer patients will be coinfected with tuberculosis.
Control strategies
To date, public-health eff orts promoting early detection and rapid treatment (by active case fi nding and health education) have achieved the best results in terms of morbidity and costs of the disease. 7, 60 However, unlike tuberculosis, early detection and treatment will not decrease transmission, as human-to-human transmission is very rare. In a focus in southern Australia, limitation of irrigation from a contaminated water source has been associated with a dramatic reduction of new Buruli cases. 61 A randomised controlled trial done in 1976 in Uganda 62 provided evidence of a 47% short-term protective eff ect (6 months to 1 year) of BCG vaccination against Buruli ulcer. The trial did not determine whether BCG off ered long-lasting protection. Two case series from Benin 63 and Cameroon 64 suggested that BCG vaccination could protect children against severe forms of the disease (osteomyelitis and multiple lesions).
Inexpensive prevention strategies such as wearing protective clothing when farming and the immediate cleansing of traumatic skin injuries might also help.
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Future perspectives
The discovery of the plasmid harbouring the genes responsible for mycolactone production and the sequencing of the complete genome of M ulcerans 67 together provide a fundamental resource for researchers. The identifi cation of M ulcerans-specifi c antigens might help to develop a genetic vaccine. The knowledge of the genome will reveal enzymes involved in pathogenesis and potential virulence factors, which might promote the development of new drugs targeting these specifi c pathways. A better understanding of the molecular epidemiology might help to discover how the disease is transmitted.
Where do we go from here? Table 3 summarises the current situation and future research needs. More general data are required regarding the incidence and risk factors for Buruli ulcer disease.
Until the mode of transmission is fully understood, general environmental measures to protect communities cannot be defi ned. If the role of aquatic bugs in transmission or as intermediary hosts is confi rmed, preventive environmental measures such as the ones used for schistosomiasis could be applied-eg,
Current situation, main problems
Research and development needs
Burden of disease
Emerging disease due to environmental factors Under-reporting of the disease through passive surveillance system Huge socioeconomic impact in the most aff ected communities mainly due to late diagnosis High recurrence rate National prevalence surveys for identifying new foci and mapping Develop strategies for active case fi nding Make Buruli ulcer a nationally reportable disease in aff ected areas Improve reporting system through the existing community-based surveillance system 68 Also, the sequencing of the M ulcerans genome could help in identifying specifi c antigens from which a plasmid DNA genetic vaccine could be developed. 69, 70 Now that the combination of rifampicin and streptomycin recommended by WHO has been implemented in several Buruli ulcer endemic countries (eg, Benin, Cameroon), it is diffi cult to do randomised controlled trials to determine the eff ectiveness of this approach. Therefore, it is essential to ensure close monitoring and data collection for all Buruli ulcer cases treated with the WHO recommended treatment, describing precisely the treatment schemes in use, the results regarding the localisation and clinical form of Buruli ulcer, reduction of the ulcer size or oedema, speed of healing, relapse rate, side-eff ects, impact on the extension of the surgery, and long-term impact on tuberculosis (ie, the development of resistant forms). Additionally, feasibility and cost-eff ectiveness should be evaluated. Sitafl oxacin, rifalazil, epiroprim, and the diaryquinolone R207910 should be tested in combination with other antimicrobial agents. Pharmacokinetic and/ or pharmacodynamic modelling needs to be considered before clinical studies are planned, so that appropriate human doses are used. Meanwhile, there is an urgent need to identify cheap, safe, and eff ective oral combinations of antibiotics. There is also a need to properly assess the eff ects of heparin on antibiotic penetration with studies that compare groups of patients on antibiotic treatment with or without heparin. Also, because the necrotic lesions are caused by the production of mycolactone, further work should look at the possibility of developing new drugs aimed at inhibiting the toxin or its production.
PCR is a quick and sensitive test for detecting M ulcerans, and the new dry reagent form would make it easier to use in practice. However, it is very expensive and requires punch biopsies for the non-ulcerative stage of the disease. It would be desirable to have rapid and non-invasive diagnostic tests that can be carried out in the fi eld. There are hopes for serodiagnostic assays for early detection based on M ulcerans-specifi c antigens. 1 However, it is uncertain how specifi c these tests will be in areas where all the members of aff ected communities are exposed to this environmental pathogen. Also, operational research is required to test the eff ectiveness and applicability of these new tests in remote villages with little infrastructure. Detection strategies will need to defi ne the target groups, the optimal screening frequency, and how to access the most aff ected populations. The added value of these tests compared with clinical examination in endemic areas might be questionable when the easiest and quickest treatment of most of the nodules is excision.
Buruli ulcer was declared an emerging disease in 1998. The WHO Department of Control of Neglected Tropical Diseases has recently created a Technical Advisory Group on Buruli ulcer, which will provide advice to WHO and its partners on all aspects of Buruli ulcer control and research. Buruli experts have invested much eff ort in research. The recent sequencing of the M ulcerans genome opens new prospects and hope for the future of Buruli ulcer management. However, these prospects are still far in the future, and such hopes should not obscure the fact that when the disease is tackled in the early stages, treatment is extremely simple and cost-eff ective. Eff orts should be directed towards developing strategies for early diagnosis and treatment of the disease, including health education for the most aff ected populations to increase awareness and change misguided beliefs about the disease, training of health-care workers on early detection and minor surgery, and the implementation of outreach activities (eg, active case fi nding, health education) in the most aff ected areas.
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Search strategy and selection criteria
We identifi ed information for this review through a PubMed search (English and French) up to October 2005, and references from relevant articles together with other published data of the WHO website and unpublished data presented at annual WHO advisory group meetings on Buruli ulcer. Search terms were "Buruli" OR "Mycobacterium ulcerans".
